Both are highly effective, well-studied, and dramatically better than anything we had a decade ago
Oral semaglutide (Rybelsus)
Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
Tirzepatide is a dual-agonist that activates both GLP-1 and GIP receptors
Live Chat Not offered on site, but 24/7 text support is available Email Support [email protected] We received a response within 12 hours of emailing them
Levels stabilize within a relatively narrow range that fluctuates slightly but remains generally constant
